Blocking Haem Signaling Revives Exhausted Cancer-Fighting T Cells
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
Summary
When immune T cells wear out fighting cancer, they lose the ability to keep attacking tumors. This study uncovers why: damaged mitochondria trigger the cellular trash-disposal system (the proteasome) to break down proteins, releasing a molecule called haem. That free haem then disables a key gene regulator called BACH2, pushing T cells into a burned-out state. Researchers found that blocking this haem pathway preserved T cell vitality and boosted anti-tumor power. Remarkably, manufacturing CAR-T cell therapies — engineered immune cells used in leukemia treatment — in the presence of bortezomib, an already FDA-approved drug, prevented exhaustion and improved treatment outcomes. This opens a practical, near-term route to making CAR-T therapies more durable and effective for cancer patients.
Detailed Summary
T cell exhaustion is one of the biggest obstacles in cancer immunotherapy. When immune cells are chronically exposed to tumors, they gradually lose their killing ability and enter an exhausted state — reducing the effectiveness of therapies like CAR-T cell treatment. Understanding and reversing exhaustion could dramatically improve outcomes for cancer patients.
This study, published in Nature, investigated why exhausted CD8+ T cells — the frontline killers of the immune system — accumulate dysfunctional mitochondria and eventually burn out. The researchers discovered a previously unknown signaling chain: depolarized, damaged mitochondria trigger elevated proteasome activity (the cell's protein-degradation machinery), which selectively breaks down mitochondrial proteins. This breakdown releases free regulatory haem — an iron-containing molecule — into the cell.
The liberated haem then enters the nucleus and disrupts BACH2, a transcription factor critical for maintaining T cell stemness and function. With BACH2 disabled, T cells lose regenerative capacity and slide deeper into exhaustion. Crucially, blocking haem's nuclear entry preserved BACH2 activity, restored T cell vigor, and enhanced anti-tumor efficacy in preclinical models.
The clinical translation is compelling. In patients with B cell acute lymphoblastic leukemia (B-ALL) receiving CD19-targeted CAR-T cells, higher proteasome gene expression in the CAR-T product correlated with worse outcomes. When CAR-T cells were manufactured in the presence of bortezomib — an FDA-approved proteasome inhibitor already used in multiple myeloma — T cell exhaustion was reduced and therapeutic efficacy improved.
This research identifies a druggable mitochondria-proteasome-haem-BACH2 axis governing T cell fate. Because bortezomib is already approved and clinically available, this finding has a plausible near-term path toward improving adoptive cell therapies. Caveats include reliance on abstract-level detail and the need for clinical trial validation of the bortezomib-during-manufacturing strategy.
Key Findings
- Damaged mitochondria activate the proteasome, releasing haem that silences BACH2 and drives T cell exhaustion.
- Blocking haem's nuclear entry preserved BACH2, restored T cell stemness, and boosted anti-tumor activity.
- Higher proteasome gene expression in CAR-T cells negatively correlated with patient outcomes in B-ALL.
- Manufacturing CAR-T cells with bortezomib (FDA-approved) reduced exhaustion and improved efficacy in preclinical models.
- The mitochondria-proteasome-haem axis is a novel druggable target to optimize adoptive cell immunotherapy.
Methodology
The study used CD8+ T cell models to trace the mitochondria-proteasome-haem-BACH2 pathway mechanistically, combined with human patient data from B-ALL CAR-T cell trials correlating proteasome gene signatures with outcomes. Ex vivo CAR-T manufacturing experiments tested bortezomib as an intervention to reduce exhaustion before cell infusion.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting detail on methodology, effect sizes, and statistical rigor. The bortezomib manufacturing strategy has not yet been validated in prospective human clinical trials. Some competing interests are disclosed among senior authors.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.